ABBV Long Call Strategy
ABBV (AbbVie Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV (AbbVie Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $368.38B, a trailing P/E of 101.64, a beta of 0.31 versus the broader market, a 52-week range of 176.57-244.81, average daily share volume of 6.9M, a public-listing history dating back to 2013, approximately 55K full-time employees. These structural characteristics shape how ABBV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.31 indicates ABBV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 101.64 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. ABBV pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on ABBV?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current ABBV snapshot
As of May 15, 2026, spot at $210.80, ATM IV 25.84%, IV rank 43.94%, expected move 7.41%. The long call on ABBV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long call structure on ABBV specifically: ABBV IV at 25.84% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 7.41% (roughly $15.61 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABBV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABBV should anchor to the underlying notional of $210.80 per share and to the trader's directional view on ABBV stock.
ABBV long call setup
The ABBV long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABBV near $210.80, the first option leg uses a $210.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABBV chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABBV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $210.00 | $6.75 |
ABBV long call risk and reward
- Net Premium / Debit
- -$675.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$675.00
- Breakeven(s)
- $216.75
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
ABBV long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on ABBV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$675.00 |
| $46.62 | -77.9% | -$675.00 |
| $93.23 | -55.8% | -$675.00 |
| $139.83 | -33.7% | -$675.00 |
| $186.44 | -11.6% | -$675.00 |
| $233.05 | +10.6% | +$1,629.97 |
| $279.66 | +32.7% | +$6,290.76 |
| $326.27 | +54.8% | +$10,951.56 |
| $372.87 | +76.9% | +$15,612.35 |
| $419.48 | +99.0% | +$20,273.15 |
When traders use long call on ABBV
Long calls on ABBV express a bullish thesis with defined risk; traders use them ahead of ABBV catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
ABBV thesis for this long call
The market-implied 1-standard-deviation range for ABBV extends from approximately $195.19 on the downside to $226.41 on the upside. A ABBV long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ABBV IV rank near 43.94% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on ABBV should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABBV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABBV-specific events.
ABBV long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABBV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABBV alongside the broader basket even when ABBV-specific fundamentals are unchanged. Long-premium structures like a long call on ABBV are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ABBV chain quotes before placing a trade.
Frequently asked questions
- What is a long call on ABBV?
- A long call on ABBV is the long call strategy applied to ABBV (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ABBV stock trading near $210.80, the strikes shown on this page are snapped to the nearest listed ABBV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABBV long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ABBV long call priced from the end-of-day chain at a 30-day expiry (ATM IV 25.84%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$675.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABBV long call?
- The breakeven for the ABBV long call priced on this page is roughly $216.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABBV market-implied 1-standard-deviation expected move is approximately 7.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on ABBV?
- Long calls on ABBV express a bullish thesis with defined risk; traders use them ahead of ABBV catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current ABBV implied volatility affect this long call?
- ABBV ATM IV is at 25.84% with IV rank near 43.94%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.